BTIG Research Reiterates “Buy” Rating for Humacyte (NASDAQ:HUMA)

BTIG Research reissued their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note issued to investors on Friday morning, Marketbeat.com reports. BTIG Research currently has a $10.00 price objective on the stock.

HUMA has been the topic of a number of other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Finally, Benchmark reiterated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research note on Thursday, October 10th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Humacyte presently has a consensus rating of “Buy” and an average price target of $10.00.

Humacyte Stock Up 6.2 %

Shares of NASDAQ HUMA opened at $5.34 on Friday. The company has a market capitalization of $635.91 million, a P/E ratio of -5.34 and a beta of 1.45. Humacyte has a 1 year low of $1.96 and a 1 year high of $9.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. The company has a 50 day simple moving average of $5.75 and a 200-day simple moving average of $5.95.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, equities research analysts predict that Humacyte will post -1.09 earnings per share for the current year.

Insiders Place Their Bets

In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the sale, the director now directly owns 3,677,262 shares in the company, valued at $23,350,613.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Kathleen Sebelius sold 5,182 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the sale, the director now directly owns 40,276 shares in the company, valued at $217,490.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 352,112 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the transaction, the director now directly owns 3,677,262 shares in the company, valued at approximately $23,350,613.70. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,084,153 shares of company stock worth $6,869,996 over the last three months. 23.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Humacyte

Large investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in Humacyte in the 2nd quarter valued at about $28,000. Hartline Investment Corp bought a new stake in shares of Humacyte during the first quarter valued at approximately $70,000. Principal Financial Group Inc. bought a new stake in shares of Humacyte during the second quarter valued at approximately $83,000. Profund Advisors LLC acquired a new position in shares of Humacyte during the second quarter worth approximately $97,000. Finally, XTX Topco Ltd bought a new position in Humacyte in the 2nd quarter worth approximately $110,000. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.